Table 2

Comparison of presenting clinical and laboratory findings between patients with therapy-related (t-AML) and de novo AML

Characteristict-AMLde novo AMLP
Patients, no. (%) 200 (7.0) 2653 (93.0)  
Sex, male/female, no. (%) 64 (32)/136 (68) 1409 (53)/1244 (47) < .0001 
Median age, y (range) 57.8 (18.6-79.4) 53.2 (16.2-85.0) < .0001 
WBC, × 109/L   .003 
    Median 7.4 12.5  
    Range 0.4-258 0.1-527  
    Missing 51 58  
Hemoglobin, g/dL   .04 
    Median 9.4 9.1  
    Range 4.2-13.7 2.5-20.6  
    Missing 60  
Platelet count, × 109/L   .02 
    Median 50.5 55  
    Range 2-595 4-933  
    Missing 60  
PB blasts, %   .002 
    Median 22 35  
    Range 0-100 0-100  
    Missing 20 244  
BM blasts, %   .03 
    Median 65 75  
    Range 2-100 0-100  
    Missing 17 246  
LDH value, U/L   .09 
    Median 372 413  
    Range 90-15 098 40-7627  
    Missing 108  
Characteristict-AMLde novo AMLP
Patients, no. (%) 200 (7.0) 2653 (93.0)  
Sex, male/female, no. (%) 64 (32)/136 (68) 1409 (53)/1244 (47) < .0001 
Median age, y (range) 57.8 (18.6-79.4) 53.2 (16.2-85.0) < .0001 
WBC, × 109/L   .003 
    Median 7.4 12.5  
    Range 0.4-258 0.1-527  
    Missing 51 58  
Hemoglobin, g/dL   .04 
    Median 9.4 9.1  
    Range 4.2-13.7 2.5-20.6  
    Missing 60  
Platelet count, × 109/L   .02 
    Median 50.5 55  
    Range 2-595 4-933  
    Missing 60  
PB blasts, %   .002 
    Median 22 35  
    Range 0-100 0-100  
    Missing 20 244  
BM blasts, %   .03 
    Median 65 75  
    Range 2-100 0-100  
    Missing 17 246  
LDH value, U/L   .09 
    Median 372 413  
    Range 90-15 098 40-7627  
    Missing 108  

Percentages may not add to 100 because of rounding.

AML indicates acute myeloid leukemia; BM, bone marrow; LDH, serum lactate dehydrogenase; PB, peripheral blood; and WBC, white blood count.

Close Modal

or Create an Account

Close Modal
Close Modal